Live episode from Youtube This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drvinayprasad.com/subscribe
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_00And we are live. We are live. And I'll be taking listener questions, viewer questions today. We're talking about a lot of things. But first off, we got to talk about this AML cancer vaccine. We're going to talk about the Anthropic IPO. I see it's up to $100 now from a peak of 113 and claims about whether or not they'll cure cancer. And we're going to talk about why the Washington Post is interested in the AML vaccine and all that and more. So let's get started. This AML vaccine.
SPEAKER_00I see a lot of enthusiasm for this acute myeloid leukemia vaccine. They put out a press release. The press release claims that it improves overall survival from 14.7 to 24 months in a randomized control trial of 122 patients who had achieved CR2 but were deemed ineligible for transplant. A lot of questions, a lot of questions that follow. And this has largely been press released by the company. Well, My first thing is I notice it's being covered by the Washington Post.
SPEAKER_00Now, why is the Washington Post so interested in whether or not an AML cancer therapeutic vaccine in second line AML is able to improve overall survival? And the answer, of course, is it's part of a broader news coverage about Robert F. Kennedy Jr. They're obsessed with that topic. So they're trying to link everything to him because he's had statements about vaccines. This is also a vaccine. But is it really? It's fundamentally a very different type of product than a vaccine to prevent you from getting infectious disease. This is a cancer therapeutic vaccine. People already have cancer and they inject you with some antigen
SPEAKER_00that they think will stimulate the body to fight off that cancer. In this case, it's a WT1 peptide vaccine, a target that's been known for quite some time, a technology that's been around for quite some time and a very small randomized study. Well, when I see small randomized control trials with big claims, I guess I'm a little bit critical. I'm a little bit skeptical. I want to do some digging. So I did some digging into the clinicaltrials.gov and I noticed that there are a few changes along the way that make me a little bit curious.
SPEAKER_00Number one, it was originally supposed to follow overall survival for 52 weeks. They've extended it to They've extended it to CML. Ernest puts, I have CML recently diagnosed as interesting. Well, hopefully your CML doesn't turn into AML. So in a small randomized control trial, 120-some people enrolled, the first thing I look at is the power calculation. You want to make sure that the authors pre-specified what power calculation and overall survival analysis they're going to run and that they faithfully executed
SPEAKER_00on that plan. In clinicaltrials.gov, when I went to the first iteration, I noticed that the trial was supposed to follow survival for 52 weeks, and the most recent iteration has been extended to five years. I noticed that the company says that after 80 deaths, they analyze a survival analysis, and that's when they find the benefit, the p-value is like 0.032. The question, of course, is were there any interim analyses? Because then, of course, you're going to spend some alpha, and that p-value may not be significant. But they tell me this was the first analysis, so I have to take that at face value.
SPEAKER_00That's really interesting that they waited for 80 deaths in the study to do even one analysis. That's quite interesting. Yeah. Then of course they get a whopping nine or 10 months survival benefit. We don't see that often in AML, that's practically unheard of. So when a small potentially underpowered randomized trial has an extremely large result, I think many people always say small studies underpowered, there's a huge risk of a false negative, failing to detect a result that actually exists. But there's also a risk of false positive and exaggerated results,
SPEAKER_00finding a benefit that's too good to be true and that's exaggerated. And it makes you worry about that. At least one analysis said they wanted 140 patients. I don't see that they quite got there. I also think the pretest probability that sort of an old target and an old technology would work in a very difficult disease has got to be there, has got to be something people wonder about. Finally, the study is unblinded, but overall survival tends to be a bias-resistant endpoint. But blinding could potentially mean that you have differences in follow-up and visits.
SPEAKER_00I think the authors anticipated some of that. They built in some protocol changes around that to make sure that people are followed equally, but we'll see what they actually generated. I saw some commenters online. They say, well, now we have an overall survival benefit in AML, an overall survival benefit in melanoma. Cancer vaccines are succeeding after all these years. Wait just a second. First of all, when it comes to melanoma, I've not seen an overall survival benefit. I've seen a relapse-free survival benefit I've seen that. I've not seen an overall survival benefit.
SPEAKER_00I'm curious to see that. I've also not seen whether or not that benefit could be captured by neoadjuvant therapy if you just leave the tumor in and give the adjuvant pembrolizumab. I haven't seen that. In the case of the AML drug, small underpowered studies often require replication, particularly when they make bold claims. And so in this particular instance, I'm much more skeptical than I think the broader community. Meanwhile, I see the Washington Post article has like a thousand retweets. Everyone is jumping on, talking about how great this is, how exciting.
SPEAKER_00I see a lot of people commenting, but fewer oncologists, because I think people who've done this for some time know that the probability a cancer therapeutic vaccine works in AML is very, very low. And the probability that it would have such a big benefit is very, very low. And this is a small study from a company I've not heard of. There are a lot of more questions that need to be asked. Now, some people were like saying, would this be suitable for registration? I don't know. Possibly, possibly. That doesn't say much.
SPEAKER_00That doesn't say that it actually works, for instance. So, you know, I'm a bit skeptical about that. What else to say about this? I think, oh, the other thing to say is they're transplant ineligible. You know, all these AML trials, they say they're ineligible for intensive chemotherapy. They're ineligible for transplant. You know, ineligibility isn't a badge you wear. It says, I'm ineligible. I'm eligible. It's a judgment that's continually made and updated. And sometimes different doctors can disagree on what's transplant eligible.
SPEAKER_00Some people can think that one person is eligible. They're fit enough to do it. Another person think maybe not. There's disagreement there. It's a subjective decision. It's an eyeball decision. And I'm very skeptical of people living this long who are deemed ineligible. I suspect that many of them may in fact have been eligible for a transplant, wrongly deemed not eligible. And if you achieve CR2, maybe you should take them to transplant and maybe they look better now that they've achieved CR2 than they did before. And so a lot of open questions there too.
SPEAKER_00Finally, what should the control arm be for someone in CR2? I saw one option was observation, but then hydroxyurea every time the counts go up. Not exactly everyone's preferred option there. And so that raises a bunch of questions, raises a bunch of questions about whether or not the control arm was appropriate. Ultimately, small underpowered studies create often spurious estimates of benefit. And I think that's something that the community hasn't really fully appreciated. Ernest is back. Let's see. Love your videos. Great to see them.
SPEAKER_00And ZDogg taking Semblix. And so far, so good. Taking Semblix. What is that? Acimitinib. Let's see. Semblix. So far, so good. That's interesting. Acimitinib. Acimitinib. Okay. And three months. Oh, wow. I guess... I'd be curious, Ernest, why they picked asimitinib. That's the newest one. And I'm glad to see that the white blood count is down. You know, the drugs for CML, particularly newly diagnosed CML, work super well.
SPEAKER_00Imatinib works super well. Nilotinib works super well. Ducdasatinib works super well. Asimitinib we know less about. And I've written a bunch of articles in this space about frontline treatment for CML over the years. And CML is a remarkable story in oncology. CML is a story where it was once Median survival of three to four years. And now in the most recent Swedish data set, life expectancy for CML is on par with the life expectancy for an age sex match control. It's like normal life expectancy within the bounds of the confidence interval.
SPEAKER_00Really probably one of the greatest stories in oncology over the last 30 years and what we should aspire to in all tumor types. Ate SLS? Ate? Fred's saying that he ate, and that's the name of the peptide vaccine, the WT1 peptide vaccine for AML. Oh, thank you. Somebody writes, would love to have you as a professor for my MPH. Where are you doing your MPH? I'm here at UCSF. We don't offer an MPH. We offer an MSCI, Masters of Science in Clinical Investigation.
SPEAKER_00Is that what they call it? Berkeley offers the MPH, and I did my MPH at Hopkins, which was good, which was good a while back, about a decade ago. CR letters. I saw a lot of people talking about a big CR letter that appeared this week from Summit Therapeutics, and they were saying, oh, the FDA is saying they want overall survival, blah, blah. The first thing I said was, if what you're going on is what a drug company says the CR letter contained, well, You're completely missing the point. Okay.
SPEAKER_00The drug company, what they summarize the CR letter as saying is not what the CR letter says. Okay. And then a few days later, the CR letter appeared and lo and behold, there's a bunch of other things that were not captured by the company's press release. And interestingly, Reuters ran the story. I really have to ask myself, how can a news outlet just print what a company says without even an ounce of critical thinking or skepticism? And that completely baffles me. Which brings me to Dario.
SPEAKER_00I see Dario has made a lot of big claims about cancer and all these people in the AI boom have made big claims about cancer. And don't get me wrong. I'm very bullish about AI. I think it will fundamentally transform the medical experience. It'll fundamentally transform cancer care and how all care is delivered. I'm very bullish on it. I think it's For people who are in cognitive fields, like my own field, we should be deeply worried that we have a thinking machine that can think better than 90% of people doing this.
SPEAKER_00And that's astonishing and staggering. The thing about thinking machines is they can do, you know, so many day to day tasks in medicine better and probably give you better opinions and better guidance. You know, Ernest, you should put in all your lab values into Claude Fable or GPT Astra and ask which treatment for CML would they recommend? You know, I think it would be interesting. So this thinking machine can do those kinds of cognitive tasks really well. But what people are speculating it can do is it can,
SPEAKER_00is it can Cure diseases that are not otherwise cured. It can find insights that are not otherwise found. And I suspect in a handful of rare cases, it may make a leap connecting two disparate domains of science and find something that doesn't previously exist. That's got to be few and far between. And the biggest barrier it will face to... To curing cancer, the biggest barrier is that we simply don't understand the biology well enough, that the biology isn't there.
SPEAKER_00And you're training AI on a lot of studies that can't be reproduced, that have fundamental problems in the methods that lack good controls, that were one offs, that were in a, if you ran the experiment a thousand times, you get all these distributions and the scientist is picking the one result that's most sexy and publishing that. And these sorts of things happen all the time because the incentives in science are completely perverse. The incentives are designed so that people who want to become famous and want to become successful have to claim that they've solved AML.
SPEAKER_00I've improved survival by 10 months and have to make bold claims to get attention. That's not a great system for truth and accuracy where the biggest result of most experiments is it doesn't work. You know, people say an experiment that's negative still teaches us something. There's even a bigger thing, an experiment that you couldn't even get to run correctly, that you're still troubleshooting. That's the lion's share of experiments. And then the ones that actually give you a negative result, which are useful, and then the ones that are actual discovery, which are really small. But all of these things are being published, even the ones where there probably is something wrong with the reagents or materials
SPEAKER_00or they're detecting something incorrect. They're all being published and AI is being trained relentlessly on that. So I think Dario has one very good idea, which is they've got a lab in South San Francisco and they're rerunning experiments that different groups have claimed discovery on to see if those experiments actually translate into replication before they move forward. And I think that will allow the AM models to train better, but I'm still very pessimistic that they'll be able to make inroads in cancer within a decade. All right.
SPEAKER_00What's up? What's up, Zelda? Biggest barrier is trying to fix something they don't yet know exists, but I bet an mRNA vaccine will come. Yes, the AML vaccine is the peptide vaccine, not even mRNA vaccine. Does it have bad adverse events? Yes, the mRNA COVID vaccine does. I'm being asked a question about cancer treatment with ivermectin and fibendazole. What are your thoughts? Are there credible studies? Well, they're not credible studies. I don't see any credible.
SPEAKER_00A very simple study you could do is take a bunch of people who are coming with cancer. Half of them get their usual treatment plus fibendazole. Fibendazole, half of them get usual treatment without Fibendazole, and then you can measure survival. They've not done that. There've been a lot of anecdotes where somebody says somebody had a transformative outcome on Fibendazole or Ivermectin, but the problem with that anecdote is they also got chemotherapy two weeks before. They also got surgery or something else is going on. And then somebody says, well, I've never seen the chemotherapy work that well.
SPEAKER_00Okay, but if you give it to a thousand people, some people works really well in, some people works less well in, and this could just be, you know, the top 10th percentile. You don't know what the drug is adding unless that's the only thing you give in isolation. That's why we do randomized studies. Yeah, I know. I don't know why it found a zeitgeist. Well, those are those topics. I never hear great stuff for Paxlovid. That's funny. Well, Paxlovid failed in the most recent randomized control trial.
SPEAKER_00In two very large randomized studies, Paxlovid failed to reduce hospitalizations and death panoramic and what was it, COVID Cove or something, some other study, two paired studies in the New England Journal of Medicine. Yeah. So I also, you know, I've heard a bunch of people who took it and they claimed that their symptoms got better in the first day or two. And some people complained about rebound. Um, but, uh, that's about all for there, that topic.
SPEAKER_00Are you doing renovations too? Yes, I'm playing around. I'm, I'm moving to a new office studio space. So I'm setting it up and I'm really doing this kind of as a test run to see how it goes. I hope people really benefit. Yeah, of course. I hope people benefit from all treatments, including that AML peptide vaccine, which probably is not going to replicate. But yeah, I even had a person related to the vaccine post on our high school group chat. Yeah, that AML vaccine has caught the zeitgeist. And maybe it's true, but it certainly probably requires a replication randomized control trial.
SPEAKER_00I doubt that it will be broadly accepted without that. It seems our current cancer treatment is so barbaric. You would think that in all these years we'd have a better choice in treatments. I think to CK Milano, that is a very good point. It is often barbaric. And one wonders why the treatments are still so primitive. We've had a number of advances in immunotherapy, in tyrosine kinase inhibitors, but we still, the backbone of treatment still is cytotoxic chemotherapy. I think one of the reasons why cancer is so hard to treat is that the difference
SPEAKER_00between a parasite and your body, a bacteria and your body, those are big differences. There are many differences. The difference between a cancer cell and your healthy cell We talk about loads of mutations and all these things. But from a 30,000-foot view, they're actually really, really similar. That it's so similar to who we are, it's very hard to kill the cancer cell and not to kill us in the process. They're just so similar. They use the same pathways. They're so similar. They have largely the same DNA.
SPEAKER_00And so I think we forget how close cancer is to who we are. And really, what is cancer? It's a cell or cells in the body that no longer serve the overall goal of the body, but are rather rebellious and serve their own goals. And that's a challenge and it can happen anywhere in the body where these cells can go rogue. What do you think about bacillus subtilis for defense against staph warriors? I don't know enough about that. Okay, just looking at inflammatory stuff and horrible nutrition and lack
SPEAKER_00of regenerative abilities, often lack of sunlight. I definitely think healthy people, the biggest thing they can do is sleep better, lower their stress, get some more sunlight, eat better, lose weight, don't smoke, don't drink too much. I worked at a library doing asbestos abatement in 2010. Am I at risk for mesothelioma? I worked there for four months. Sadly, I mean, in 2010, hopefully they had some precautions in place like ventilation. But for people who are exposed to asbestos,
SPEAKER_00there is a risk that's sustained for decades and decades afterwards. I don't know enough about the circumstances of that workplace. By 2010, they had been a lot of rules in different states about making sure asbestos abatement is done safely. Medical student from Germany here, big fan. Any must have book recommendations for becoming a great internal medicine physician? Morexella Kataralis, good name, medical student from Germany. Well, that's a great question. So what books did I really like?
SPEAKER_00Let me go through them. I thought Complications and Better by Gawande, the first two books, were really, really good. And I think all of his later books are less good. Being mortal was also sort of a return to his form, except I have some disagreements about the management of the case of his father and the lesson he takes away. I think he didn't take away the right lesson. The lesson is his father probably should never have gotten radiation. That was the beginning of the end. And the moment you start doing things without randomized data and rare tumors,
SPEAKER_00the moment you start doing things without randomized data and rare tumors in people who have no detectable disease, the moment you get into some problems. What other books do I like? Extended Phenotype and the Selfish Gene by Dawkins. I know it's a little bit not medicine, but I think it gives you a good medical perspective. House of God by Sam Shem. What's the name? Steven Bergman, the psychiatrist. You know, is it fully applicable to the modern age? Maybe not, but it's a classic for a reason.
SPEAKER_00I really like the books by Gil Welsh, Should I Be Tested for Cancer? Maybe Not, Here's Why, Overdiagnosis, Becoming Sick in Pursuit of Health. I'm biased towards ending medical reversal and malignant, of course, books I know something about. I think the first Sid Mukherjee book, The Emperor of All Maladies, is really worth reading. I read so many other. Oh, When the Air Hits Your Brain by Frank Vertosik. If you're interested in neurosurgery, I thought that was a great book. Do you feel, Walter Bortz, do you feel that direct to consumer advertising should be illegal?
SPEAKER_00Well, I feel like it shouldn't exist. It's terrible. I was just watching a TV show on one of the few networks that still have ads, and I hadn't seen ads in so long, and I just saw a litany of god-awful pharmaceutical drug advertisements that are uninformative, that don't capture nuance, and that it's hard to imagine you can advertise to the general public for such a niche disease and still turn a profit, but surely it does have return on investment, otherwise they wouldn't do it. Okay, so I don't think it should exist, but how do you get rid of it?
SPEAKER_00If you passed a bill to make it illegal, probably the Supreme Court would overturn it under grounds of free speech. If you had given more authority to the FDA to regulate it, that will be met with political pressure every time they try to regulate it. Should it be outright illegal to advertise pharmaceutical products? Maybe I certainly, I'm not gonna be defending the ads. I don't think the ads have anything, do any good other than drive sales towards products that a good medical device or drug does not need an ad to drive sales to. So I definitely, I'm not a fan of them.
SPEAKER_00Sells and health dies fast and gets brought back only slowly. I think that's a good lesson. Robin Cook. I think the only Robin Cook book I read was, what was it? Outbreak long time ago. I did like the Hot Zone by Richard Preston. Are you the Arthur Fonzarelli of randomized controlled trials? Was that a Happy Days reference? So that's before my time. Did I ever look into LDL stuff from David Fellman, aka the lipid model? No, I've never looked into David Fellman. Do you think new RAS drugs should do head-to-head trials for approval against duress
SPEAKER_00on cue for pancreas cancer? Oh, that's a really good question. And the answer is, yeah, they should. I think there's one or two that are kind of grandfathered that they're mostly completed accrual before RAS on Q. But let's say you're launching a study tomorrow or a month from now. Absolutely. Yeah, RAS on Q should be your control arm. And then, you know, it will really pop that balloon because they may not be able to win. But another way to put it, meow, meow, meow. Meow meow is the handle of the person asking the question.
SPEAKER_00Another way to put it is that realistically, by the time they generate a result, will be so much past these first generation RAS inhibitors. They'll be probably multi next generation RAS inhibitors. And so I think they'll face headwinds with trying to get market share. Get out of my emergency room, Gomer. Yeah, that was from House of God. Classic. Are you going to forego colon cancer screening when you turn 45? Well, thankfully, I'm not yet at that age. Thankfully, I'm not yet at that age. First of all, 45 is a made up number. All right.
SPEAKER_00The randomized data and all recommendations until just a couple of years ago were 50. All right. So they've moved it to 45 because of Chadwick Boseman. And some modeling study, they moved it to 45. I'm not sure they have evidence for that. We published on that topic. And if you do get colon cancer screening, I tend to think Flexig is the best. We did a really nice video with Brett Hauser, the PI of the Nordic study on colonoscopy. You can check it out on this channel. Meow meow. I mean, look at all the lies during COVID that got debunked. Okay. Yeah.
SPEAKER_00Well, I think most of the problems during COVID were pushed by the public health establishment, which hasn't learned any lessons. Any notable genes associated with cancer? I uploaded raw DNA from 23andMe to Prometheus. I have genotypes associated with FGFR2, TNRC9. Boy, probably lots. I don't know how much of the genome 23andMe actually sequences. I'd be curious to know that. If you had a magic wand, this is AC8583.
SPEAKER_00If you have a magic wand, what are the best bang for buck things that would change the healthcare system, reduce the gap between when somebody gets a disease and when they start getting treatment? Oh, wow. That's a great question. I think that... If I had a magic wand, the best thing to do, I think one thing I want to say off the bat is this person is making a really good point that there are really important things between when somebody starts to notice they're losing weight, has night sweats, and maybe has chest pain when they swallow food.
SPEAKER_00From that moment to when you get diagnosed, worked up and start your treatment for that, we want that to be very, very timely. And it's not in the current system. And I think one of the reasons why it's not is that doctors and hospitals, they fill up their schedules and calendars with very low value medical practices that probably don't work. They're doing so much junk that when the things that really matter come through, they don't clear the schedule for that because the junk is putting more food on the table than the useful things.
SPEAKER_00So if I could wave a magic wand, what I would do is I would take 5% of the federal government healthcare expenditures, including subsidizing insurance premiums, 5% of what we spend on healthcare. And use it to run a clinical trials agenda where all we do is test current standards of care against alternative or lesser approaches, what to omit. The more we cut out things that don't work, prove definitively that it's a waste of our time, the more time we will have for things that do work. And so I think that right now there's an incentive in medicine to add to the bloat
SPEAKER_00and the bureaucracy to add another Peptide vaccine without really asking, does this actually work? And that's the biggest bias in healthcare. Anyone who can back B.B. Trumpenstein after 30 million can't be trusted. Okay. Well, that's an odd one. I don't recall backing any politician. Once age, just because you go work in an administration, yeah, we should ask this question. If you're asked to work in a governmental administration and you believe you have knowledge and skills,
SPEAKER_00you should do it because the alternative will be somebody with less knowledge and less skills doing a worse job. So it's really a public service, even if you agree with the person or disagree with the person. If there's a future democratic president, they asked me to go do something and I think I can do a better job than others, then I will do it. Came across an old video of yours where you suggested a division of the NIH that's dedicated to running RCTs. Is this an area that deserves additional funding and do you see this happening? Ari, that's a great question. That's exactly what I'm referring to. Yeah. Um, I do think that a huge, like right now the entire federal budget
SPEAKER_00on science is like 40 billion, 50 billion, but most of that is for like pipetting, you know, completely diverted, but just the amount we spend on healthcare, we don't know works hundreds of billions of dollars. How much should you spend to test that? Five billion, 10 billion, some percentage of that, how much you're spending every year you should test. If you worked at Xerox, you would spend some percentage trying to figure out how to become more efficient. We don't do that in healthcare. Now, I'm not sure it should belong in the NIH. I'm not sure that that's the right place for it. I think it would require careful consideration of how to structure it.
SPEAKER_00Yeah, somebody's asking, did you ever meet or speak to Trump? No, I didn't. Zelda, I think a problem sits at the top of the hierarchy chain and that people lower in the chain are trying to do their best in the chaotic world. Absolutely. I think that's a big truth, which is that a lot of people who work in healthcare are doing their very best, but the powers that be in the system itself is incentivizing bad medicine. Okay. Jay Bhattacharya is doing so well, but somehow his goal for reducing animal model research hasn't changed at all. I wish there was some type of crowdsourced way to rank NIH grants in reporter.
SPEAKER_00Oh, that's a great idea. They should allow direct comments and reporter. I love Jay, he's a friend of mine, but reforming science has been very, very difficult and everyone is wedded to doing what they want to do. And I personally think animal models that are often We are taking millions of animals each year, effectively torturing them. And the yield from that is occasionally some bits of information, but often noise. And that's absolutely unacceptable.
SPEAKER_00And there's very little incentive to completely reform that because there are a lot of people who make a lot of money from breeding and keeping and holding those animals for animal torture. And there's a lot of people who think that the experiments that torture the animals give useful information. And what I would want them to prove is that the experiments do and that they recapitulate human biology. And I don't think they've done that. And so I would gradually phase those out. Actually, I would do it rather very aggressively if I had that opportunity. Speaking of NIH, what percent of funded research is actually useful? Why?
SPEAKER_00Very little. Yeah, most of it is wasted, I think. You know, I would do a simple thing at NIH, which is you just sample, you know, 50 experiments from Harvard, from Yale, from different labs, just sample them randomly and replicate them. And if you can't get the same result, then you start cutting fundings to those institutions and then put the pressure on the institution to make sure the science that's published from that place is actually reproducible. And I think that would obliterate them because they are completely hooked on federal funds. They're addicted to federal funding.
SPEAKER_00That is the great lever in the system. What do you think about having an observational study on nurse patient ratios and adverse outcomes? Is it too obvious that one person can do a thousand things? Oh, good question. I would say we should have a randomized study on that very question because I bet that too few nurses bad up to a certain point nurses optimal. Too many nurses probably maybe even bad again or wasteful. So I would like to try to find that sweet spot. It could do forearm, five arm cluster randomized control trial to get at that.
SPEAKER_00Are there some new drugs vying for third-line CRC that seem to have close efficacy but differing adverse event profile? What happened? Am I back? Would you rather put your patient on a drug with high diarrhea or high heme tox? Meow, meow. Meow, meow. That's a good point. Was meow, meow the student or who's meow, meow? Yeah, how do you know so much about oncology? Yeah, really good point. I would say that, look, for quitinib,
SPEAKER_00tipfluoracil, triuracil, lawnserve, what else do we got? We got so many things. I don't think any of them are great drugs. They're all just terrible drugs. And if you pull the randomized studies for all those terrible drugs, you often find we went up against a control arm of best supportive care. That's not the appropriate standard of care at the time. Even in the 1990s, we were giving 5-FU again and again and again. And in the people eligible for these studies, there will still be a response rate to older drugs.
SPEAKER_00Sometimes, meow meow, I think that going back to Oxali, if you haven't seen in a long time, going back to 5FU and giving it a different way, that might generate a better result than putting them back on these things. And there are entire strategies that haven't been tested. In the 80s and 90s, people would sometimes just give people a toposide or things like that. And it's hard to believe that these newer drugs, extremely costly, are much better than those things. Ari says there should be a way for the public to vote on grants. I absolutely think that's true.
SPEAKER_00And I actually think that there should be a way for the public to leave comments on these grants. Talk in the press about the NIH's weeding out grants that use the word diversity and that they accidentally got a grant that said T-cell diversity, which is not actual diversity. But I think if the public actually read the Biden-era DEI grants, the language in that, the public's head would explode. Pregnant people, persons of color, all this woke stuff is just riddled in all these grants that have nothing to do with that or shouldn't have anything to do with that.
SPEAKER_00And I think that there should be a vote on that. Serious question. What do you think made you such an independent thinker and compassionate person? Oh, that's a very sweet comment, Kelly. I hope to be those things. You never know if you are those things. I feel like, I don't know. When I hear something, I try to think about it. And when I hear a situation, I try to be compassionate. But I'm not always compassionate. I think that some people... Particularly people who I think should know better, I don't have much compassion for.
SPEAKER_00And so those are the people I were critical of during the pandemic. Firemen in Chicago being offered whole body scans paid by the union. I talked to a 30-year-old who had it done. Talk about a waste of resources. Maybe a six-year-old might benefit, but not a 30-year-old. Patrick Murray, that's an excellent point. If you're going to offer a whole body scan, the 30-year-old is not who I would think about it. Yeah, I think that that's dying.
SPEAKER_00I don't think that the average person thinks experts are smarter than them. I think the pandemic rid people of that illusion. The problem with that is there's not been a reasonable substitute and the media And I think that there is a group of people who still blindly defer to expertise and they are aligned with one political party more than the other these days. What attracted you to He Monk? Is the state of the specialty today what you expected to be when you began? Ari.
SPEAKER_00Ari, what's your field? Tell me, I'm curious, but I'll tell you. What attracted me to He Monk was You know, I wanted to do something in medicine where you feel like everything you do matters. And you certainly feel that in Hemonc, like it always matters. It matters to be good. It matters to be knowledgeable. We're not taking care of something where you could say like, boy, you know, there are certainly some times in medicine where I was like, if this doctor didn't exist and the healthcare system didn't exist, this person would be better off and they don't even need a doctor.
SPEAKER_00We run the gamut in Hemonc from I certainly think we do some things that we don't need to do and you can try to, in your own practice, prevent a patient from doing those things. We cure some people. We definitely cure diseases and cure people and that's very satisfying and validating. We help people live longer and better when they're facing a malady and sometimes we provide comfort and care. And so I feel like it's probably one of the most validating fields
SPEAKER_00Is the field what you expected when you began? No. When I started, I felt like and I still feel like a lot of the people in it are in it for the right reason, but that the biases and financial pressures are so strong, it pulls them in the wrong way. And I sincerely thought that if you point that out and you logically explain why that's in the wrong direction, people will course correct. And I tried to do that for the first five, 10 years of my career, but I don't feel like they went in that right direction.
SPEAKER_00I think it's just gotten worse. The financial pressures have gotten worse. The bad medicine has gotten worse and it's more captured than ever before. What is your opinion on routine mammograms, PSA screening, and colonoscopy? Student for life. I think I've written a lot about this, but PSA screening I think is really negative evidence. We're talking about USPSTF grade D at one point, and then the urologist popped the champagne when they made it grade C. And you have many, many randomized studies.
SPEAKER_00You pull them all together. There's no improvement in all-cause mortality. And some but not all studies have an improvement in prostate-specific mortality. But you have to cut out a lot of prostates to achieve that victory. That, to me, is not a very favorable screening test. Mammograms. Also, to me, the evidence base is so antiquated. It's in a world where breast cancer treatment was so barbaric and doesn't really apply to the modern day. It really needs new randomized studies, colonoscopies. We have the Nordic trial. Listen to my interview with Brett Hauser, the PI of the Nordic study.
SPEAKER_00Somebody writes, were you a genius pre-med school? I don't believe. I've never classified myself as that. I would say that I was good in some school subjects, but very bad in others. If I'm not interested in something, I'll be very bad at it to this day. All right. Let's see. Oh, Ari says, I'm a senior in college, but hope to be a doctor one day. Wow. That's great. Ari asked so many great questions. You should definitely do it, Ari.
SPEAKER_00Email me if I can ever help. Plenary Session Podcast at gmail.com or my contact me page on my website. Thoughts on the revised food pyramid? Should it be modified? Fuego. Fuego, that's a really good question. I guess I would say, I guess one thing we'll all agree on. It was better than the garbage food pyramid before. Okay, that I think we'll all agree. It's better than what was there before. But I've never met anyone in my life who looks at that food. I've never met it. I don't know anyone who's like, I'm thinking about what to eat today.
SPEAKER_00Let me look at the food pyramid. What does the government advise me? So I guess if I were really to study it, the first thing I would be like is, are people responsive to governmental guidance? Question mark. If people are responsive to governmental guidance, what kind of guidance helps them? And then I would say, what type of pyramid, when presented to people, change how they eat and whether or not they're obese and things like that. I would think that rather than the food pyramid, which I don't think has much impact, subsidies for corn and sugar,
SPEAKER_00rules around school lunch programs, Potentially taxes on ultra-processed food or ways to punish ultra-processed food, I think, or even reporting how much processing went into your food. I think those would have a greater impact. Let's see. Patrick Murray, they look at me like crazy when I say I don't get the scan. They also, and I don't know who voted for it in the union, but they should have asked me, the firefighter nurse. Yeah, absolutely. The U.S. food pyramid should have three words, everything in moderation.
SPEAKER_00Yeah, absolutely. Your opinion on the REDUCE-IT trial that used mineral oil in the placebo group against omega-3 EPA. Yeah, that's a really good question, Moraxxella. Remind me, is this the VSEPA study? Let me look it up. REDUCE-IT, is that VSEPA? Yes, it's VSEPA. Oh, that's terrible. It's a really good study. First of all, Is Vaseppa better than a mineral oil enema?
SPEAKER_00I mean, the mineral oil, I guess what people need to know about this study. Fish oil has failed in many, many randomized studies. Vaseppa is a particular type of fish oil that contains one part of the one compound in fish oil, but not the other compounds. And Vaseppa claimed a benefit that it actually worked when all the other fish oils failed. So it's possible that Visepa has the perfect fish oil that like eating the blowfish and then the sushi master has carved it just right. Or there's something fishy about the study, no pun intended.
SPEAKER_00And what's fishy about the study is the control arm. You're swallowing capsules of mineral oil. And mineral oil, when swallowed in a certain volume, can impair the absorption of statins and things like that. And I think many of us worry that the reason that trial won was the control arm was getting so much mineral oil that it prevented them from getting effective medications. And that was actually harmful. I tend to hold that view. And so I've not been persuaded on Visepa. And I believe I wrote a paper on that trial. Confirmatory evidence is required for things with one study, Alison Haslam and myself.
SPEAKER_00Celda writes, what about the question whether you eat food that fuels you or food that is empty calories and how much do you care about health on a case-by-case basis? I totally agree that I think this idea that all calories are equal is a false idea. There are certainly garbage foods that probably should be reduced or eliminated. All right, good question, Patrick. In the 1990s, US public schools served a slop that no doubt had a negative effect on everyone, says Fuego. Absolutely. I think they still serve slop and that's the problem. And that's what Callie was talking about in his Rogan interview. Meow, meow.
SPEAKER_00Do you have any opinions on the Treasury Department possibly restricting U.S. pharmacy companies from buying drugs from China? Good for U.S. innovation or detrimental for patients? That's a really great question. That's a really great question. I guess I would say a few things. One is I think it would be great for the U.S. to retain the title of The best place to develop biomedical products and devices. I think that that is a national security concern and that's something really important to the United States.
SPEAKER_00So I totally agree with that, number one. Two, if somebody makes something in China that really is curative or transformative, there's no law or regulation that will be able to hold that back. That's going to burst through. Truly transformational things are going to burst through. Three, how can you Operate on pharmaceutical companies buying drugs from China. I don't know. I would do, I would tread lightly, you know, legend that CAR T, uh, that is a Chinese CAR T and it works really well.
SPEAKER_00And there've been a number of drugs that were dealt from China and now there are lots of smaller companies that are taking next in class drugs from China and bringing them over. Um, so it could be detrimental to patients. So I think it's a very difficult place and maybe rather. And then the last thing is China has some advantages that the United States doesn't have. I've said this in a prior thing, but this idea that in the United States that if you enroll people on a trial, you need informed consent to back and forth. These cultural norms don't exist so strongly in China. There are undoubtedly people on clinical trials in China who probably,
SPEAKER_00if you quiz them, they won't be able to answer all the questions. I mean, I'm sure that's true in America. It's probably worse in China. And they're just being pushed on the studies. And if you have a billion people and you can push people on studies, you can run studies better than anybody. So if we really wanted to be great and beat China, I think we would invest in a clinical trials apparatus. Roham. Thoughts on interventional oncology? I'm a medical student interested in the field. I don't even know what that is. I know interventional radiology, interventional oncology. I don't know.
SPEAKER_00I don't know what they're doing. I'd be curious. All right. Is that every question? No. Oh, somebody asked, Patrick Murray, I want to know how schools have to feed their kids no matter... Matter with the Food Pyramid. I think that there are a number of places where you can codify into law nutritional requirements for kids that are beyond the pyramid and that those are really good opportunities to strike. So I wouldn't mess around with the pyramid too much.
SPEAKER_00Ari writes, would you recommend getting an MPH? Oh, you sent me an email, Ari? I never, what the heck? Let me look. Oh, Squarespace, found it. All right, I'll reply. I will reply, Ari. But the short answer is no. I would say that...
SPEAKER_00The short answer is no, Ari. I think that if you do an MPH, you should do it later in your career when it's within a year, you're stuck in some fellowship program anyway. That's when I did it. I don't think you should do it before you go to medical school. And I will reply to your email now that I found it. Do you have any insight into what stocks to buy? No, I don't. Or I might, but I wouldn't want to say that. I want to know... Like does the food pyramid have any effect on that kind of funding and what kids get fed? I mean, yeah, I think that the food pyramid is something that's broadly
SPEAKER_00for the public, the public dissemination of nutrition, and that there are more specific rules around childhood, child nutrition programs. Thoughts on tight glucose control for cancer. Again, this is a really good question. I'm open to a randomized study that shows that that has a survival advantage. And If that does, I would be very interested to see it. Bowman Ramani, how do you feel about Moderna being 220 a share?
SPEAKER_00Well, I don't have too much. I don't have any skin in that game. But what I would say is that I suspect it's so high because many people believe that mRNA cancer therapeutic vaccines will work in other tumor types and work more broadly. And I've written some things on my Substack at drvinayprasad.com where I would be more pessimistic with that thesis. But I guess we will learn a lot with RCC and urethelial cancer. Kelly writes, will you ever come speak in person on the East Coast,
SPEAKER_00particularly greater Philadelphia area? I've done it a bunch of times. And if I get an invite, I will consider coming. Let me know. But no plans at this moment. All right. Well... Done 45 minutes, lots of great questions. Maybe, Harmony2 showed, okay, Ivonesumab had a statistics in OS in advance. What's going on? Oh, right.
SPEAKER_00This was, Ari, you must've come late. I mentioned it. The CR letter is public. You can read the CR letter. And what the company says is the reason is not the reason. I think it's because... Wait, Harmony 2 or Harmony 1? Harmony 2, Harmony 1. But either way, check out the CR letter, Ari. Thank you, Mark. I'll be back with more of this. And I got to get back with Zubin soon. But to Ari's point, I mean, the biggest reasons are just like the number
SPEAKER_00and percentage of events that occur in China versus elsewhere. And I think, you know, trust but verify is always my role, particularly with China. I think the CR letter is really nicely presented. It's available on the website right now. All right. We'll be back with more. And thanks. Moraxella, send me an email, Moraxella. You must be an oncologist somewhere. All right. Until next time.
Elizabeth Holmes/ AI researchers start smoking/ Moderna vax by Plenary Session This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit...
Pope has cancer; Phase 1 trials for AI; Can AI hack cancer trials__1 by Plenary Session This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit...